75% of cancer clinical trials in the US and UK have criteria that needlessly exclude or underdose patients with a blood type common in folks of African or Middle Eastern descent, a new study has found🩸my story here! www.fiercebiotech.com/research/75-...

Cancer trials improperly exclude, underdose patients with common non-white blood type, study finds

Hundreds of millions of people who live in, or are descended from, regions where the malaria-causing protozoan Plasmodium vivax is prevalent have inherited a unique blood type that evolved to preve | ...